• For ASYMPTOMATIC patients (or those with only minimal symptoms, such as palpitations) and any tachycardia with a rate of approximately 100 -120 with a normal blood pressure, consider CLOSE OBSERVATION or fluid bolus rather than immediate treatment with an anti-arrhythmic medication. For example, a patient's "usual" atrial fibrillation may not require emergent treatment. • All Adenosine administrations should be immediately followed by a 20ml rapid flush. • Typical sinus tachycardia is in the range of 100 to (200 -the patient's age) beats per minute. • Symptomatic tachycardia usually occurs at rates of 120 -150 and typically ≥ 150 beats per minute. Patients who are symptomatic with heart rates < 150 likely have impaired cardiac function, such as CHF. • Serious Signs / Symptoms include: Hypotension; acutely altered mental status; signs of shock/poor perfusion;
chest pain with evidence of ischemia (e.g. STEMI, T-wave inversions or depressions); and acute CHF. • Search for underlying cause of tachycardia such as fever, sepsis, dyspnea, etc.
• If patient has a history or if 12-Lead ECG reveals Wolfe Parkinson White (WPW), use caution with Adenosine and give only with a defibrillator immediately available. • Regular Narrow-Complex Tachycardias:
• Adenosine may be considered to assist with rhythm diagnosis or if a patient has a history of Adenosine conversion. • Adenosine may not be effective with atrial fibrillation/flutter, yet is not harmful and may help identify rhythm. • Synchronized Cardioversion is recommended to treat UNSTABLE atrial fibrillation/flutter and monomorphicregular tachycardia (SVT). • Monitor for respiratory depression and hypotension associated with Midazolam. • Continue pulse oximetry and EtCO 2 monitoring is required for all narrow complex tachycardia patients.
• Providers must export all monitor data to EHR when caring for and treating narrow complex tachycardia patients.
